was formed to acquire leading contract
research organizations (CRO’s) focused on specialty therapeutic areas such as
endocrinology. The first acquisition of SRI, Diabetes & Glandular
Disease Research Associates (DGD) specializes in providing Phase
I and II/III clinical research investigative services to prominent
pharmaceutical and biotechnology companies focused on diabetes,
obesity and other endocrine and metabolic therapeutic areas.
Headquartered San Antonio, Texas
As compounds have grown more complex and high profile
disease states such as diabetes, heart disease, and cancer
have become more prevalent, specialty CRO’s with significant
intellectual capabilities and access to specific study participants
(i.e. diabetics) have become increasingly more important to
sponsor customers. As a result, endocrine/metabolic clinical
trial markets are expected to achieve annual growth in excess
of the overall CRO industry.
Specialty Research has the potential of
becoming an industry leader in the highly fragmented and growing
CRO industry by executing a buy and build strategy focused
upon the acquisition of other specialty therapeutic CRO’s
(diabetes, obesity, hormonal, etc.) while developing best-in-class
infrastructure and service capabilities.
